Maia S, Ayachi Hatit N, Paycha F
Service de pharmacie et radiopharmacie, hôpital Bretonneau, CHRU de Tours, France.
Ann Pharm Fr. 2011 May;69(3):155-64. doi: 10.1016/j.pharma.2011.02.003. Epub 2011 Apr 7.
Molecular imaging has shown its interest in the diagnosis, staging and therapy monitoring of many diseases, especially in the field of cancer. This imaging modality can detect non-invasively early molecular changes specific to these diseases. Its expansion includes two aspects linked firstly with the advanced techniques of imaging modalities and secondly with the development of tracers as radio pharmaceuticals for imaging new molecular targets. Technetium-99m ((99m)Tc), because of its physical characteristics, its widespread availability and low cost, is the most used radionuclide in molecular imaging with the technique of single photon emission computed tomography (SPECT). Nevertheless, the current difficulty concerning the supply and the great interest of Positron Emission Tomography (PET), the "competitor" imaging modality-using molecules labelled with fluorine-18 ((18)F), legitimates the question about the future of (99m)Tc, its supremacy and the emergence of new tracer labelled with (99m)Tc. Focusing on the actual and future supply situation, the place of SPECT imaging in nuclear medicine, as well as the development of new molecules labelled with (99m)Tc is necessary to show that this radionuclide will remain essential for the speciality in the next years.
分子成像已在多种疾病的诊断、分期及治疗监测中展现出其价值，尤其是在癌症领域。这种成像方式能够非侵入性地检测出这些疾病特有的早期分子变化。其发展包括两个方面，一方面与成像方式的先进技术相关，另一方面与作为用于成像新分子靶点的放射性药物的示踪剂的开发有关。锝-99m（99mTc）因其物理特性、广泛可得性及低成本，是单光子发射计算机断层扫描（SPECT）技术在分子成像中最常用的放射性核素。然而，当前关于供应的困难以及正电子发射断层扫描（PET）——使用氟-18（18F）标记分子的“竞争”成像方式——的巨大吸引力，使得关于99mTc的未来、其优势地位以及新型99mTc标记示踪剂的出现的问题变得合理。关注实际和未来的供应情况、SPECT成像在核医学中的地位以及新型99mTc标记分子的开发，对于表明这种放射性核素在未来几年对该专业仍将至关重要是必要的。
